Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 18:2020:4020249.
doi: 10.1155/2020/4020249. eCollection 2020.

An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease

Ke Pei #  1 , Ting Gui #  2   3   4 , Dongfang Kan  2   3   4 , Huichao Feng  5 , Yanqiang Jin  6 , Ying Yang  2   3   4 , Qian Zhang  7 , Ziwei Du  8 , Zhibo Gai  2   3   4   9 , Jibiao Wu  1 , Yunlun Li  7   10
Affiliations
Review

An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease

Ke Pei et al. Biomed Res Int. .

Abstract

The occurrence of nonalcoholic fatty liver disease (NAFLD) is associated with major abnormalities of hepatic lipid metabolism. We propose that lipid abnormalities directly or indirectly contribute to NAFLD, especially fatty acid accumulation, arachidonic acid metabolic disturbance, and ceramide overload. The effects of lipid intake and accumulation on NAFLD and NAFLD treatment are explained with theoretical and experimental details. Overall, these findings provide further understanding of lipid metabolism in NAFLD and may lead to novel therapies.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest regarding the publication of this paper.

References

    1. Loomba R., Sanyal A. J. The global NAFLD epidemic. Nature Reviews Gastroenterology & Hepatology. 2013;10(11):686–690. doi: 10.1038/nrgastro.2013.171. - DOI - PubMed
    1. Lonardo A., Byrne C. D., Caldwell S. H., Cortez-Pinto H., Targher G. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(4):1388–1389. doi: 10.1002/hep.28584. - DOI - PubMed
    1. Younossi Z. M., Koenig A. B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi: 10.1002/hep.28431. - DOI - PubMed
    1. Bessone F., Razori M. V., Roma M. G. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cellular and Molecular Life Sciences. 2019;76(1):99–128. doi: 10.1007/s00018-018-2947-0. - DOI - PMC - PubMed
    1. Magee N., Zou A., Zhang Y. Pathogenesis of nonalcoholic steatohepatitis: interactions between liver parenchymal and nonparenchymal cells. BioMed Research International. 2016;2016:11. doi: 10.1155/2016/5170402.5170402 - DOI - PMC - PubMed